These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 28618976)
1. Bromelain-decorated hybrid nanoparticles based on lactobionic acid-conjugated chitosan for in vitro anti-tumor study. Wei B; He L; Wang X; Yan GQ; Wang J; Tang R J Biomater Appl; 2017 Aug; 32(2):206-218. PubMed ID: 28618976 [TBL] [Abstract][Full Text] [Related]
2. Bromelain-immobilized and lactobionic acid-modified chitosan nanoparticles for enhanced drug penetration in tumor tissues. Wang X; He L; Wei B; Yan G; Wang J; Tang R Int J Biol Macromol; 2018 Aug; 115():129-142. PubMed ID: 29665385 [No Abstract] [Full Text] [Related]
3. Acid-degradable lactobionic acid-modified soy protein nanogels crosslinked by ortho ester linkage for efficient antitumor in vivo. Cheng X; Qin J; Wang X; Zha Q; Yao W; Fu S; Tang R Eur J Pharm Biopharm; 2018 Jul; 128():247-258. PubMed ID: 29730261 [TBL] [Abstract][Full Text] [Related]
4. Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors. Kong F; Tang C; Yin C Bioconjug Chem; 2020 Oct; 31(10):2446-2455. PubMed ID: 32991164 [TBL] [Abstract][Full Text] [Related]
5. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin. Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730 [TBL] [Abstract][Full Text] [Related]
6. Lactobionic acid-modified thymine-chitosan nanoparticles as potential carriers for methotrexate delivery. Wang J; Zhang Z; Ai Y; Liu F; Chen MM; Liu D Carbohydr Res; 2021 Mar; 501():108275. PubMed ID: 33657498 [TBL] [Abstract][Full Text] [Related]
7. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release. Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840 [TBL] [Abstract][Full Text] [Related]
8. Doxorubicin delivery to 3D multicellular spheroids and tumors based on boronic acid-rich chitosan nanoparticles. Wang X; Zhen X; Wang J; Zhang J; Wu W; Jiang X Biomaterials; 2013 Jun; 34(19):4667-79. PubMed ID: 23537667 [TBL] [Abstract][Full Text] [Related]
9. Hybrid nanoparticles based on ortho ester-modified pluronic L61 and chitosan for efficient doxorubicin delivery. Xu X; Xue Y; Fang Q; Qiao Z; Liu S; Wang X; Tang R Int J Biol Macromol; 2021 Jul; 183():1596-1606. PubMed ID: 34022312 [TBL] [Abstract][Full Text] [Related]
10. Preparation of collagen peptide functionalized chitosan nanoparticles by ionic gelation method: An effective carrier system for encapsulation and release of doxorubicin for cancer drug delivery. Anandhakumar S; Krishnamoorthy G; Ramkumar KM; Raichur AM Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):378-385. PubMed ID: 27770906 [TBL] [Abstract][Full Text] [Related]
11. Fabrication of self-assembled chitosan-dispersed LDL nanoparticles for drug delivery with a one-step green method. Tian J; Xu S; Deng H; Song X; Li X; Chen J; Cao F; Li B Int J Pharm; 2017 Jan; 517(1-2):25-34. PubMed ID: 27845214 [TBL] [Abstract][Full Text] [Related]
12. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Misra R; Sahoo SK Eur J Pharm Sci; 2010 Jan; 39(1-3):152-63. PubMed ID: 19961929 [TBL] [Abstract][Full Text] [Related]
13. Ligand-directed stearic acid grafted chitosan micelles to increase therapeutic efficacy in hepatic cancer. Yang Y; Yuan SX; Zhao LH; Wang C; Ni JS; Wang ZG; Lin C; Wu MC; Zhou WP Mol Pharm; 2015 Feb; 12(2):644-52. PubMed ID: 25495890 [TBL] [Abstract][Full Text] [Related]
14. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery. Lee JY; Chung SJ; Cho HJ; Kim DD Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228 [TBL] [Abstract][Full Text] [Related]
15. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced. Song X; Wang J; Xu Y; Shao H; Gu J Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022 [TBL] [Abstract][Full Text] [Related]
16. Chemosensitizing indomethacin-conjugated chitosan oligosaccharide nanoparticles for tumor-targeted drug delivery. Lee JY; Termsarasab U; Lee MY; Kim DH; Lee SY; Kim JS; Cho HJ; Kim DD Acta Biomater; 2017 Jul; 57():262-273. PubMed ID: 28483700 [TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy. Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047 [TBL] [Abstract][Full Text] [Related]
18. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization. Yu JM; Li YJ; Qiu LY; Jin Y J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361 [TBL] [Abstract][Full Text] [Related]
19. pH-sensitive bromelain nanoparticles by ortho ester crosslinkage for enhanced doxorubicin penetration in solid tumor. Wang X; Xu J; Xu X; Fang Q; Tang R Mater Sci Eng C Mater Biol Appl; 2020 Aug; 113():111004. PubMed ID: 32487411 [TBL] [Abstract][Full Text] [Related]
20. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]